Please ensure Javascript is enabled for purposes of website accessibility

Why Amarin Corporation's Stock Is on the Mend Today

By George Budwell – Nov 15, 2018 at 1:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Amarin's business update at an investor conference helped to calm investors' nerves today.

What happened

Shares of Amarin Corporation (AMRN) are regaining lost ground today following a business update at the Jefferies London Healthcare Conference. As of 11:20 a.m. EST, Amarin's stock was up by 15.2% in the wake of this conference presentation. During the presentation, the company's CEO, John F. Thero, provided additional color on the company's recent cardiovascular outcomes trial, REDUCE-IT, for its sole commercial-stage product, Vascepa. 

A man in a suit bending a downward-trending red arrow upward.

Image Source: Getty Images.

So what

Amarin's shares were getting walloped after the company's presentation at the American Heart Association meeting in Chicago last weekend. Following that presentation and an accompanying paper published in the New England Journal of Medicine covering REDUCE-IT's results, the drugmaker's shares dropped by as much as 25% in just two days of trading (Monday and Tuesday of this week).

The big concern was the potential role the study's mineral oil placebo may have had in skewing the results in Vascepa's favor. Thero, per his remarks today, downplayed this concern, noting that he believes the placebo used in REDUCE-IT was indeed "inert."

Now what

Amarin is moving to gain a label expansion for Vascepa stateside for the REDUCE-IT patient population. However, Thero said that the company is also pursuing an approval in Europe following these unprecedented results. To do so, the company may entertain partnering offers in European territories, per the company's remarks today. Any partnering deal would likely come with a sizable up-front payment and a favorable royalty rate, lessening the possibility of another capital raise.

While a European deal doesn't seem imminent, the groundwork has clearly been laid for future partnerships abroad, as well as an expansion of the drug's label to include a cardioprotective indication inside the United States. As such, Amarin's stock should continue to push higher in the days and weeks ahead.

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Stock Quote
$1.17 (%)

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.